STAT6 and STAT1 Pathway Activation in Circulating Lymphocytes and Monocytes as Predictor of Treatment Response in Rheumatoid Arthritis

Show full item record



Permalink

http://hdl.handle.net/10138/176514

Citation

Kuuliala , K , Kuuliala , A , Koivuniemi , R , Kautiainen , H , Repo , H & Leirisalo-Repo , M 2016 , ' STAT6 and STAT1 Pathway Activation in Circulating Lymphocytes and Monocytes as Predictor of Treatment Response in Rheumatoid Arthritis ' , PLoS One , vol. 11 , no. 12 , 0167975 . https://doi.org/10.1371/journal.pone.0167975

Title: STAT6 and STAT1 Pathway Activation in Circulating Lymphocytes and Monocytes as Predictor of Treatment Response in Rheumatoid Arthritis
Author: Kuuliala, Krista; Kuuliala, Antti; Koivuniemi, Riitta; Kautiainen, Hannu; Repo, Heikki; Leirisalo-Repo, Marjatta
Contributor: University of Helsinki, Medicum
University of Helsinki, University of Helsinki
University of Helsinki, University of Helsinki
University of Helsinki, University of Helsinki
University of Helsinki, Clinicum
University of Helsinki, Clinicum
Date: 2016-12-12
Language: eng
Number of pages: 15
Belongs to series: PLoS One
ISSN: 1932-6203
URI: http://hdl.handle.net/10138/176514
Abstract: Objective To find novel predictors of treatment response to disease-modifying antirheumatic drugs (DMARDs), we studied activation of STAT (signal transducers and activators of transcription) 6 and 1 in circulating leukocytes of patients with rheumatoid arthritis (RA). Methods 19 patients with untreated recent-onset RA, 16 patients with chronic RA irresponsive to synthetic DMARDs and 37 healthy volunteers provided blood samples for whole blood flow cytometric determination of intracellular STAT6 and STAT1 phosphorylation, expressed as relative fluorescence units, in response to IL-4 and IFN-gamma, respectively. Phosphorylation was restudied and treatment response (according to European League Against Rheumatism) determined after 1-year treatment with synthetic DMARDs in recent-onset RA and with biological DMARD in synthetic DMARD-irresponsive RA. Estimation-based exact logistic regression was used to investigate relation of baseline variables to treatment response. 95% confidence intervals of means were estimated by bias-corrected bootstrapping and the significance between baseline and follow-up values was calculated by permutation test. Results At baseline, levels of phosphorylated STAT6 (pSTAT6) induced by IL-4 in monocytes were higher in those who achieved good treatment response to synthetic DMARDs than in those who did not among patients with untreated RA (OR 2.74, 95% CI 1.05 to 9.47), and IFN-gamma-stimulated lymphocyte pSTAT1 levels were higher in those who achieved good treatment response to a biological drug than in those who did not among patients with chronic RA (OR 3.91, 95% CI 1.12 to 20.68). During follow-up, in recent-onset RA patients with good treatment response to synthetic DMARDS, the lymphocyte pSTAT6 levels decreased (p = 0.011), and, consequently, the ratio of pSTAT1/pSTAT6 in lymphocytes increased (p = 0.042). Conclusion Cytokine-stimulated STAT6 and STAT1 phosphorylation in circulating leukocytes was associated with treatment response to DMARDs in this pilot study. The result, if confirmed in larger studies, may aid in developing personalized medicine in RA.
Subject: CITRULLINATED PROTEIN ANTIBODIES
TUMOR-NECROSIS-FACTOR
IFN-GAMMA
DISEASE-ACTIVITY
CLINICAL-RESPONSE
INTERFERON-GAMMA
FLOW-CYTOMETRY
FACTOR-ALPHA
EXPRESSION
MECHANISMS
3111 Biomedicine
3121 Internal medicine
Rights:


Files in this item

Total number of downloads: Loading...

Files Size Format View
file.pdf 2.365Mb PDF View/Open

This item appears in the following Collection(s)

Show full item record